Risk factors of uroporphyrinogen decarboxylase deficiency:
Some affected people may experience the development of liver problems such as hepatic siderosis, which is an iron buildup in the liver, steatosis, portal triaditis, an inflammation of certain liver regions, and thickening and scarring around the portal vein (periportal fibrosis).
1. The chance of developing cirrhosis, a liver disease marked by scarring, or hepatocellular carcinoma, a kind of liver cancer, may be higher in affected people than in the general population. Except in older people with recurrent disease, advanced liver disease is rare. Sometimes an underlying problem, such hepatitis C infection, causes liver damage.
2. Alcohol use, certain illnesses like hepatitis C or HIV, and the use of certain medications like estrogens are additional risk factors that have been linked to uroporphyrinogen decarboxylase deficiency.
3. According to certain research, smoking increases the risk of uroporphyrinogen decarboxylase deficiency in people who are vulnerable. Less frequently, PCT seems to be linked to specific chemical exposures (such hexachlorobenzene), kidney dialysis, and lupus.
4. These risk factors are thought to lower hepcidin levels in the body, which then causes iron to build up in the liver. However, it is unclear how exactly the majority of susceptibility variables relate to the onset of symptoms in PCT. For instance, it is obvious that in some cases, alcohol clearly plays a role in the development of the condition, but PCT is uncommon in alcoholics.
5. Three or more factors are present in the majority of uroporphyrinogen decarboxylase deficiency patients.
6. Some people experience uroporphyrinogen decarboxylase deficiency, without having a known susceptibility factor, which implies the presence of others, as of this writing, unknown risk factors.
Painful, blistering skin lesions that develop on sun-exposed skin (photosensitivity),Hyperpigmentation,Abnormal and excessive hair growth
Fragile skin,Liver issues
Antimalarial drugs chloroquine and hydroxychloroquine